PTCT
PTC Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-37/100
Last price
63.70
▲ 0.05 (0.08%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
64.57
Prev close
63.65
Day high
65.27
Day low
62.92
Volume
1.26M
Market cap
$5.32B
P/E (TTM)
—
52W range
61.23 – 90.87
Day trading desk
Gap from prior close
+1.45%
Prior close 63.65
VWAP
63.76
-0.09% from price
Relative volume
1.74×
Unusually busy
Session range
3.73%
62.92 – 65.27
Position in range
33%
Mid range
ATR (14D)
2.16
3.39% of price
Prior day high
64.47
PDH
Prior day low
62.60
PDL
Bid / ask spread
—
Quote not published
Session volume
2.00M
Avg 1.15M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.94%
-3.9%
1M
-8.08%
-9.2%
3M
-28.08%
-32.6%
6M
-8.45%
-26.6%
YTD
-16.14%
-30.4%
1Y
-2.55%
-19.0%
3Y
+184.25%
+102.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PTCT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-84.36K
Net selling
Buy transactions
16
206.02K shares
Sell transactions
21
290.38K shares
Net transactions
+37
Buys less sells
Sell : buy shares
1.4 : 1
Mixed
Insider-held shares
6.10M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | SCHMERTZLER MICHAEL Director |
SELL | 20.00K | $1.35M | Indirect |
| Aug 27, 26 | SCHMERTZLER MICHAEL Director |
SELL | 25.00K | $1.81M | Indirect |
| Aug 20, 26 | SCHMERTZLER MICHAEL Director |
SELL | 25.00K | $1.81M | Indirect |
| Aug 17, 26 | BOULDING MARK ELLIOTT Officer |
SELL | 2.81K | $204.13K | Direct |
| Aug 17, 26 | BOULDING MARK ELLIOTT Officer |
CONVERSION | 2.81K | $72.27K | Direct |
| Aug 4, 26 | KLEIN MATTHEW B Chief Executive Officer |
SELL | 10.29K | $705.72K | Direct |
| Jul 14, 26 | GRAVIER PIERRE Chief Financial Officer |
SELL | 3.49K | $280.74K | Direct |
| Jul 9, 26 | ALMSTEAD NEIL GREGORY Chief Technology Officer |
SELL | 2.46K | $222.38K | Direct |
| Jul 9, 26 | ALMSTEAD NEIL GREGORY Chief Technology Officer |
CONVERSION | 2.46K | $114.67K | Direct |
| Jul 9, 26 | SMITH MARY L Director |
SELL | 15.83K | $1.43M | Direct |
| Jul 9, 26 | SMITH MARY L Director |
CONVERSION | 15.83K | $680.07K | Direct |
| Jul 7, 26 | ALMSTEAD NEIL GREGORY Chief Technology Officer |
SELL | 46.77K | $4.09M | Direct |
| Jul 7, 26 | ALMSTEAD NEIL GREGORY Chief Technology Officer |
CONVERSION | 46.77K | $1.82M | Direct |
| Jul 6, 26 | BOULDING MARK ELLIOTT Officer |
SELL | 5.08K | $432.12K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALMSTEAD NEIL GREGORY |
Chief Technology Officer | 63.20K | Sale |
BOULDING MARK ELLIOTT |
Officer | 105.27K | Sale |
GOLDEN LEE SCOTT |
Officer | 79.11K | Sale |
GRAVIER PIERRE |
Chief Financial Officer | 83.99K | Sale |
KLEIN MATTHEW B |
Chief Executive Officer | 383.87K | Sale |
PAUWELS ERIC |
Officer | 73.41K | Sale |
SCHMERTZLER MICHAEL |
Director | — | Sale |
STEELE GLENN D JR |
Director | 22.50K | Stock Award(Grant) |
UTTER CHRISTINE MARIE |
Officer | 70.20K | Sale |
ZELDIS JEROME B. M.D., PH.D. |
Director | 22.50K | Stock Award(Grant) |
Fundamentals
Market cap$5.32B
Enterprise value$6.11B
Revenue (TTM)$1.01B
Gross profit$503.96M
EBITDA$171.22M
Net income$-38.38M
EPS (TTM)$-0.65
Free cash flow$-286.80M
Total cash$2.23B
Total debt$3.02B
Book value / share$-1.99
Shares outstanding83.46M
Float73.69M
Short % of float15.82%
Dividend yield0.00%
Beta (5Y)0.49
Valuation & profitability ratios
Trailing P/E—
Forward P/E23.80
PEG ratio—
Price / sales—
Price / book—
EV / revenue6.05
EV / EBITDA35.66
Gross margin49.96%
Operating margin41.32%
Profit margin-3.81%
Return on equity—
Return on assets2.46%
Debt / equity—
Current ratio3.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.73B | $806.78M | $937.82M | $698.80M | +114.5% |
| Operating revenue | $1.73B | $806.78M | $937.82M | $698.80M | +114.5% |
| Cost of revenue | $47.01M | $57.40M | $65.49M | $44.68M | -18.1% |
| Gross profit | $1.68B | $749.38M | $872.34M | $654.12M | +124.7% |
| Research & development | $455.25M | $534.48M | $666.56M | $651.50M | -14.8% |
| Selling, general & admin | $347.14M | $300.91M | $332.54M | $326.00M | +15.4% |
| Total operating expense | $827.13M | $896.13M | $1.22B | $1.09B | -7.7% |
| Operating income | $856.51M | -$146.75M | -$349.40M | -$439.93M | +683.7% |
| Net interest income | -$152.23M | -$166.99M | -$129.18M | -$90.87M | +8.8% |
| Pre-tax income | $696.62M | -$363.12M | -$696.11M | -$587.49M | +291.8% |
| Tax provision | $13.97M | $176.00K | -$69.51M | -$28.47M | +7,840.3% |
| Net income | $682.64M | -$363.30M | -$626.60M | -$559.02M | +287.9% |
| Net income to common | $682.64M | -$363.30M | -$626.60M | -$559.02M | +287.9% |
| Basic EPS | 8.58 | -4.73 | -8.37 | -7.79 | +281.4% |
| Diluted EPS | 7.78 | -4.73 | -8.37 | -7.79 | +264.5% |
| EBIT | $848.85M | -$196.13M | -$566.93M | -$496.62M | +532.8% |
| EBITDA | $887.66M | -$120.46M | -$330.34M | -$367.78M | +836.9% |
| Basic shares | 79.53M | 76.85M | 74.84M | 71.73M | +3.5% |
| Diluted shares | 88.31M | 76.85M | 74.84M | 71.73M | +14.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $984.65M | $779.71M | $594.00M | $279.83M | +26.3% |
| Cash & short-term investments | $1.95B | $1.14B | $876.74M | $410.70M | +70.7% |
| Accounts receivable | $181.62M | $158.55M | $160.82M | $155.61M | +14.5% |
| Inventory | $79.65M | $23.19M | $30.58M | $21.81M | +243.4% |
| Total current assets | $2.27B | $1.37B | $1.22B | $693.78M | +66.5% |
| Property, plant & equipment | $135.42M | $117.66M | $178.99M | $175.02M | +15.1% |
| Goodwill & intangibles | $471.09M | $201.13M | $461.84M | $788.23M | +134.2% |
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | +70.0% |
| Total current liabilities | $968.43M | $580.98M | $603.10M | $406.24M | +66.7% |
| Current debt | $569.63M | $257.82M | $194.31M | $72.15M | +120.9% |
| Long-term debt | $2.03B | $2.11B | $1.90B | $1.26B | -4.0% |
| Total debt | $2.71B | $2.47B | $2.23B | $1.46B | +9.6% |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | +10.7% |
| Retained earnings | -$2.96B | -$3.65B | -$3.28B | -$2.66B | +18.7% |
| Shareholder equity | -$205.31M | -$1.10B | -$818.55M | -$347.09M | +81.3% |
| Working capital | $1.31B | $784.55M | $615.53M | $287.55M | +66.4% |
| Net tangible assets | -$676.41M | -$1.30B | -$1.28B | -$1.14B | +47.9% |
| Shares issued | 81.47M | 77.70M | 75.71M | 73.10M | +4.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $682.64M | -$363.30M | -$626.60M | -$559.02M | +287.9% |
| Depreciation & amortisation | $38.81M | $75.66M | $236.59M | $128.84M | -48.7% |
| Stock-based compensation | $74.55M | $74.61M | $131.21M | $110.33M | -0.1% |
| Change in working capital | -$47.88M | $102.54M | -$4.00M | -$85.33M | -146.7% |
| Operating cash flow | $711.20M | -$107.69M | -$158.42M | -$356.65M | +760.4% |
| Capital expenditure | -$300.01M | -$74.25M | -$120.62M | -$152.46M | -304.1% |
| Investing cash flow | -$861.98M | $44.18M | -$176.74M | $290.18M | -2,051.0% |
| Financing cash flow | $331.09M | $255.87M | $646.40M | $167.95M | +29.4% |
| Free cash flow | $411.18M | -$181.94M | -$279.04M | -$509.11M | +326.0% |
| End cash position | $998.33M | $795.32M | $610.28M | $295.93M | +25.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $360.52M | $272.55M | $164.68M | $211.01M | $178.88M | +32.3% |
| Operating revenue | $360.52M | $272.55M | $164.68M | $211.01M | $178.88M | +32.3% |
| Cost of revenue | $19.92M | $28.03M | $6.95M | $15.78M | $11.42M | -28.9% |
| Gross profit | $340.60M | $244.52M | $157.73M | $195.23M | $167.46M | +39.3% |
| Research & development | $99.15M | $100.87M | $133.13M | $100.16M | $112.99M | -1.7% |
| Selling, general & admin | $80.63M | $86.18M | $96.87M | $84.05M | $85.26M | -6.4% |
| Total operating expense | $191.62M | $198.64M | $239.35M | $191.74M | $202.31M | -3.5% |
| Operating income | $148.98M | $45.89M | -$81.62M | $3.49M | -$34.86M | +224.7% |
| Net interest income | -$48.48M | -$49.03M | -$55.19M | -$32.59M | -$30.36M | +1.1% |
| Pre-tax income | $97.55M | -$2.46M | -$139.08M | -$23.07M | -$71.05M | +4,062.0% |
| Tax provision | $14.05M | $347.00K | -$4.12M | -$38.97M | -$6.20M | +3,948.7% |
| Net income | $83.50M | -$2.81M | -$134.97M | $15.90M | -$64.85M | +3,072.4% |
| Net income to common | $83.50M | -$2.81M | -$134.97M | $15.90M | -$64.85M | +3,072.4% |
| Basic EPS | 1.01 | -0.03 | -1.67 | 0.20 | -0.83 | +3,466.7% |
| Diluted EPS | 0.92 | -0.03 | -1.67 | 0.20 | -0.83 | +3,166.7% |
| EBIT | $146.03M | $46.57M | -$83.89M | $9.52M | -$40.69M | +213.6% |
| EBITDA | $161.90M | $61.98M | -$70.99M | $20.63M | -$33.11M | +161.2% |
| Basic shares | 83.01M | 82.52M | 80.69M | 78.47M | 78.15M | +0.6% |
| Diluted shares | 92.02M | 82.52M | 80.69M | 87.12M | 78.15M | +11.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.05B | $833.99M | $984.65M | $672.62M | $1.02B | — | +25.9% |
| Cash & short-term investments | $2.23B | $1.89B | $1.95B | $1.69B | $1.99B | — | +17.8% |
| Accounts receivable | $239.04M | $219.92M | $181.62M | $203.07M | $196.13M | — | +8.7% |
| Inventory | $91.35M | $75.57M | $79.65M | $52.69M | $34.06M | — | +20.9% |
| Total current assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | — | +16.1% |
| Property, plant & equipment | $126.27M | $129.43M | $135.42M | $137.65M | $113.35M | — | -2.4% |
| Goodwill & intangibles | $485.27M | $463.02M | $471.09M | $478.81M | $226.15M | — | +4.8% |
| Total assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | — | +13.3% |
| Total current liabilities | $771.07M | $923.60M | $968.43M | $866.25M | $627.81M | — | -16.5% |
| Current debt | $55.45M | $286.94M | $569.63M | $286.32M | — | — | -80.7% |
| Long-term debt | $535.52M | — | $2.03B | — | $286.01M | $285.71M | — |
| Total debt | $696.47M | $395.09M | $2.71B | $410.13M | $388.17M | — | +76.3% |
| Total liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | — | +12.0% |
| Retained earnings | -$2.88B | -$2.97B | -$2.96B | -$2.83B | -$2.85B | — | +2.8% |
| Shareholder equity | -$165.36M | -$180.47M | -$205.31M | -$155.76M | -$206.55M | — | +8.4% |
| Working capital | $1.85B | $1.33B | $1.31B | $1.14B | $1.65B | — | +38.8% |
| Net tangible assets | -$650.63M | -$643.49M | -$676.41M | -$634.57M | -$432.69M | — | -1.1% |
| Shares issued | 83.33M | 82.88M | 81.47M | 79.93M | 79.38M | — | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $83.50M | -$2.81M | -$134.97M | $15.90M | -$64.85M | +3,072.4% |
| Depreciation & amortisation | $15.87M | $15.41M | $12.90M | $11.11M | $7.58M | +3.0% |
| Stock-based compensation | $23.29M | $23.42M | $18.52M | $19.43M | $18.54M | -0.6% |
| Change in working capital | $10.19M | -$110.70M | $91.11M | -$84.88M | -$16.72M | +109.2% |
| Operating cash flow | $129.11M | -$59.04M | -$34.27M | -$66.30M | -$58.33M | +318.7% |
| Capital expenditure | -$7.14M | -$1.35M | -$37.29M | -$256.26M | -$3.92M | -428.0% |
| Investing cash flow | -$122.56M | -$93.74M | $34.01M | -$289.62M | -$422.01M | -30.7% |
| Financing cash flow | $211.88M | $6.40M | $302.50M | $15.22M | $3.96M | +3,209.0% |
| Free cash flow | $121.97M | -$60.40M | -$71.56M | -$322.57M | -$62.26M | +302.0% |
| End cash position | $1.07B | $850.43M | $998.33M | $686.30M | $1.03B | +25.4% |
Options analytics
Put / call volume
2.42
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
50.00
-21.5% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
24
Contracts, this expiry
Put volume
58
Contracts, this expiry
Heaviest call OI
65.00
0 contracts
Heaviest put OI
50.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.34 | 0.92 | +170.6% |
| Mar 2026 | -0.44 | -0.03 | +93.2% |
| Dec 2025 | -0.41 | -1.80 | -343.5% |
| Sep 2025 | -1.11 | 0.19 | +116.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.38 | 3 | $303.88M | +44.0% |
| Next quarter | 0.30 | 3 | $320.50M | +94.6% |
| Current year | 1.71 | 3 | $1.26B | -27.3% |
| Next year | 2.68 | 3 | $1.38B | +9.5% |
Analyst targets & ownership
Mean target$101.79
High target$137.00
Low target$70.00
Implied upside59.79%
Analyst count14
ConsensusNONE
Strong buy / Buy4 / 8
Hold1
Sell / Strong sell1 / 0
Held by insiders7.31%
Held by institutions122.79%
Institutions holding520
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
63.79
-0.14% from price
SMA 20
65.16
-2.24% from price
SMA 50
69.04
-7.73% from price
SMA 100
73.00
-12.74% from price
SMA 200
72.04
-11.58% from price
EMA 12
64.50
-1.24% from price
EMA 26
66.24
-3.83% from price
EMA 50
68.65
-7.21% from price
RSI (14)
39.5
Neutral
MACD (12,26,9)
-1.74
Hist 0.14
ATR (14)
2.16
3.39% of price
Realised vol 30D
32.9%
Annualised
Bollinger upper
68.62
20, 2σ
Bollinger lower
61.70
20, 2σ
50 / 200 cross
Death
69.04 vs 72.04
Trend bias
Below 200
-11.58%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.65
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
32.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.5%
Peak to trough
Max drawdown 5Y
-69.4%
Peak to trough
ATR 14
2.16
3.39% of price
Beta (reported)
0.49
5Y monthly, from filing
Short interest
Shares short
9.74M
Prior 10.22M
Change vs prior
-4.7%
Shorts covering
% of float
15.82%
Elevated
% of shares out
11.67%
Against total outstanding
Days to cover
11.4
Crowded exit
Float
73.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 14, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 13, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 20, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 7, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| May 27, 26 | Jefferies | UPGRADE | Hold | Buy |
| May 8, 26 | TD Cowen | UPGRADE | Hold | Buy |
| May 8, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| May 8, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-21
Corporate Changes & Voting Matters
8-K · 2026-08-28
Corporate Changes & Voting Matters
8-K · 2026-08-13
Periodic Financial Reports
10-Q · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-05
Headlines
Is PTC Stock Increasing Your Market Risk?
Trefis · 16h ago
Which Gives You More Of Hard-To-Replace Software, PTC Or Fair Isaac?
Trefis · 7d ago
2026 Philadelphia ORBIE Awards Honor Top Technology and Security Executives in Philadelphia
GlobeNewswire · 9d ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 11d ago
PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease
MT Newswires · 15d ago
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PR Newswire · 15d ago
PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress
Simply Wall St. · 17d ago
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
Zacks · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.